Showing 111-120 of 351 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| GABP regulation of human beta cell proliferation | The University of Texas Health Science Center at Houston | Richard Cox | Cures | 01-September-2024 to 31-August-2027 | $200.000,00 |
| The Development of 3-β-hydroxybutyrate binding protein based electrochemical micro-sensor and its application for CKM system | The University of North Carolina at Chapel Hill | Koji Sode | Improving Lives | 01-October-2022 to 30-September-2026 | $799.999,96 |
| Engineering B Cell–Targeted Microparticles to Induce Regulatory Immunity in Type 1 Diabetes | The University of North Carolina at Chapel Hill | Kristy Ainslie | Cures | 01-April-2026 to 31-March-2027 | $200.000,00 |
| Structure-switching Proteins for Continuous In Vivo C-peptide Monitoring | The University of North Carolina at Chapel Hill | Netz Arroyo | Cures | 01-October-2026 to 30-September-2029 | $892.203,85 |
| Relationships Between Executive Function Challenges and Diabetes Technology Use Among Adults with Type 1 Diabetes | The University of North Carolina at Chapel Hill | Rebecca Vitale | Improving Lives | 01-July-2026 to 30-June-2027 | $49.999,80 |
| Role of β-cell Golgi dysfunction in Type 1 diabetes pathogenesis | The University of Iowa | Samuel Stephens | Cures | 01-June-2024 to 31-May-2027 | $750.000,00 |
| Dissecting HLA Mechanisms in T1D, SLE, and MS Through High-Throughput Self-Antigen Profiling | The University of Chicago | Aly Khan | Cures | 01-September-2025 to 31-August-2026 | $150.000,00 |
| Interferons and the Integrated Stress Response: Converging Pathways in β Cell Dysfunction in Type 1 Diabetes | The University of Chicago | Charanya Muralidharan | Cures | 01-March-2026 to 28-February-2029 | $95.000,00 |
| Development of β-Cell Targeted Lipid Nanoparticle Therapeutics | The University of Chicago | Jacob Ryan Enriquez | Cures | 01-March-2025 to 29-February-2028 | $247.790,00 |
| MDA5 and TRIM21 in β-cell inflammatory signaling and autoimmunity | The University of Chicago | Kerim Kaylan | Cures | 01-July-2026 to 30-June-2028 | $100.000,00 |